Background: Some glutamatergic modulators have demonstrated rapid and relatively sustained antidepressant properties in patients with major depressive disorder. Because the potassium channel activator diazoxide increases glutamate uptake via potassium channel activation, we hypothesized that it might exert antidepressant effects by increasing the removal of glutamate from the synaptic cleft, thereby reducing excessive glutamate transmission.
A t least one third of individuals with major depressive disorder (MDD) remain treatment refractory after receiving currently available antidepressants, 1 underscoring the urgent need for new antidepressant therapies. 2, 3 Of the novel pharmacotherapeutic strategies seeking to rapidly alleviate depressive symptoms, glutamatergic modulators have emerged as promising potential targets.
In clinical studies, glutamatergic modulators such as ketamine have demonstrated rapid and relatively sustained antidepressant properties in patients with MDD 4 as well as in those with bipolar depression. 5, 6 In addition, a large body of preclinical evidence suggests that chronic administration of existing antidepressants has significant, albeit complex, dampening effects on the glutamatergic system. 7 In this context, the exquisite balance of glutamate transporters is critically important to maintaining homeostatic glutamate uptake from the extracellular space and plays a central role in modulating extracellular glutamate concentrations; these concentrations, in turn, are essential for preventing excitotoxicity in the brain. 8, 9 Astrocytic glutamate transporter dysfunction leads to excessive extracellular glutamate concentrations, which has been hypothesized to result in depressive-like behaviors in rodents, and is possibly related to the pathophysiology of depression in humans. 10 The present study sought to examine the potassium (K ATP ) channel activator diazoxide as a possible treatment for MDD. Diazoxide is Food and Drug Administration-approved for the treatment of sulfonylurea-induced hypoglycemia, hypoglycemia due to hyperinsulinemia, 11 and hypertension (https://www.accessdata. fda.gov/drugsatfda_docs/label/2008/017453s014lbl.pdf). It is available in an oral formulation, crosses the blood-brain barrier fairly rapidly, and regulates endogenous glucose production that seems to be attributable to extrapancreative (ie, central nervous system) effects via the hypothalamus, where there is increased expression of K ATP channels. 12 Diazoxide also has beneficial effects on glucose metabolism. It has been shown to suppress insulin-primarily by inhibiting insulin release from the pancreas-and to lower blood pressure and, as a result, has been studied in obese individuals. 13, 14 Dosage information available from the manufacturer notes that initial diazoxide doses in adults begin at 3 mg/kg per day (administered orally in a divided dose), with usual doses of 3 to 8 mg/day and a maximum dose of 15 mg/kg per day (Micromedex). In 1 study, obese hyperinsulinemic men received up to 900 mg/day (300 mg, 3 times a day) for 6 months; hyperglycemia and edema were doselimiting events, but only at doses higher than 300 mg/day. 13 A study by Kishore et al 12 found that equipotent diazoxide doses of 4 mg/kg per day, or 200 to 400 mg/day across species, rapidly activated the K ATP channel within 135 minutes, with corresponding maximally significant decreases in endogenous glucose production by 315 minutes. The same study found that oral administration of diazoxide substantially decreased endogenous glucose production in Sprague Dawley rats as well as nondiabetic humans without inducing significant changes in blood pressure. 12 In rats, the effects of comparable doses of oral diazoxide were abolished by intracerebroventricular administration of the K ATP channel blocker glibenclamide, thus confirming its central specificity.
Diazoxide is also known to increase glutamate uptake from the synaptic cleft by activating the K ATP channel to chronically increase expression of the excitatory amino acid transporter (EAAT)-2 system in glial cells. The activation of hypothalamic K ATP channels is key to regulating endogenous glucose production by inhibiting gluconeogenesis and negating the effect of central and systemic insulin. These measures of serial peripheral glucose and/or insulin could be used as a surrogate of target engagement of diazoxide at activating K ATP channels. 12 The EAAT-2 transporter-which is predominantly expressed on astroglial cells and is responsible for 90% of total glutamate uptake in the synaptic cleft-is one of the major glutamate transporter systems. 15 Studies suggest that astrocytic glutamate reuptake systems may be key to the pathophysiology and treatment of depression, 16 and that agents that directly increase astrocytic glutamate uptake may represent a novel class of antidepressants. 17 The present study (NCT02049385) sought to investigate whether diazoxide might exert antidepressant effects by increasing the removal of glutamate from the synaptic cleft, thereby reducing excessive glutamate transmission. This randomized, double-blind, placebo-controlled, crossover, single-site, inpatient clinical study was conducted to assess the efficacy and safety of a 3-week course of diazoxide (twice-a-day dosing, 200-400 mg total daily dose) versus a 3-week course of placebo. The proposed duration of the trial was 10 to 12 weeks.
MATERIALS AND METHODS
Male and female participants were eligible for study participation (clinical trials identifier: NCT02049385) if they were between 18 and 65 years old, met Diagnostic and Statistical Manual IV diagnostic criteria for MDD without psychotic features (confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual IV), and were currently experiencing a major depressive episode lasting at least 4 weeks. All participants were studied at the Clinical Center of the National Institute of Mental Health, National Institutes of Health, in Bethesda, MD. Participant demographics are listed in Table 1 . All participants had an initial Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20 at screening and at baseline before being randomized into the study.
Participants were randomized to order of treatment, and each course was separated by a 2-week washout period (day −14 to day 0) before the administration of either diazoxide or placebo. The starting dose of 300 mg/day, twice a day, was the treatment target for all participants unless tolerability issues ensued. The dose of diazoxide/placebo could be increased to 400 mg/day, twice a day, in subjects who did not meet response criteria by day 14; response criteria were defined as having a 50% decrease in MADRS score. If no response after 2 weeks on diazoxide/ placebo was observed, a dose of 400 mg/day, twice a day, could be given the last week in each phase for nonresponders.
The original experimental design of the study was as follows. To test surrogate neurobiological markers of antidepressant therapeutic response and/or target engagement in the brain (ie, K ATP channel activation, which is implicated in glutamate uptake), participants received an oral glucose tolerance test (OGTT) after an overnight fast using standard oral 75-g glucose loading on days 0 and 36. Oral glucose tolerance test glucose/insulin levels were calculated via the quantitative insulin sensitivity check index as a surrogate measure of decreased endogeneous glucose production or K ATP channel activation; simultaneous electroencephalography recording was used to measure pharmacokinetic and pharmacodynamic central nervous system effects (particularly gamma power in frontal regions). 18 In addition, prefrontal glutamate levels were measured using proton magnetic resonance spectroscopy, and affective and cognitive function was measured with quantitative magnetoencephalography at baseline and at the end of each treatment phase. 19 These measures were correlated with peripheral blood biomarkers obtained at baseline and during each study phase.
Participants received diazoxide or placebo 1 hour before the OGTT. Blood was sampled for glucose, insulin, and diazoxide levels at −30, 0, 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, and 240 minutes after glucose ingestion using a venous catheter. The primary clinical outcome measure was change in MADRS score from baseline to posttreatment. Adverse effects were monitored routinely.
From July 2014 to October 2015, 12 participants with treatmentrefractory MDD were recruited into the study. Six withdrew from the study before randomization, during the initial medication tapering phase. Reasons for withdrawal included improvement of symptoms (n = 1), worsening of symptoms during the drug-free period (n = 2), unrelated medical events (n = 1), and patient decision to withdraw for unknown reasons (n = 2). Among the 6 participants who progressed into the randomization phase, only 1 was able to complete the entire study; the 5 other participants withdrew from the study because of intolerable adverse effects (Table 1) .
RESULTS
Given that only 1 participant completed both treatment arms, no formal analysis of the primary outcome measure (MADRS) was possible. No short-term effect of diazoxide was apparent; at day 7, the median change in MADRS score was 0% in the 6 participants in the diazoxide condition and +10% for the 3 participants in the placebo condition (Table 1) .
Six participants completed the OGTT during the diazoxide phase, and 3 during the placebo phase. Given the small sample size, statistical comparison between conditions was not pursued. Visual inspection revealed no evidence of target engagement (Fig. 1) . Because only 1 patient completed the study, analyses of other measures were not pursued; these included electroencephalography, proton magnetic resonance spectroscopy, magnetoencephalography, and the peripheral samples.
The most common adverse effects in those participants receiving diazoxide were headache (4/6), hypotension (3/6), edema (3/6), muscle/bone/joint pain (3/6), nausea (3/6), elevated liver enzymes (2/6), weakness (2/6), stomach/abdominal discomfort (2/6), tachycardia (2/6), weight gain (2/6), and dizziness/faintness (2/6). These adverse effects were significant enough that almost all patients withdrew from the study.
DISCUSSION
Because of the significant rate of participant drop out during the medication tapering and medication administration phases, this trial was terminated before achieving the target enrollment of 20 subjects. Concomitantly, the Food and Drug Administration issued a warning for the occurrence of pulmonary hypertension in infants and newborns treated with diazoxide (https://www.fda. gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm455659.htm).
The largest literature review of diazoxide conducted to date, which included 644 cases, 20 found that this agent is implicated in a wide range of adverse effects. These include electrolyte imbalances that result in the expansion of extracellular fluid volume (hypotension, fluid retention, and edema), likely due to potent renal sodium and chloride retention but not affecting potassium excretion. Cases of pulmonary hypertension, cardiotoxicity, and/or heart failure have also been reported, likely due to the nonselective activation of the K ATP -channel, as its malfunction has been implicated in the progression of heart disease. 20, 21 In addition, rare cases of renal failure, anaphylaxis, and bone marrow suppression have also been reported. 20 In sum, the occurrence of intolerable adverse effects related to diazoxide use may preclude its investigation and use as an antidepressant agent. If future studies of diazoxide are undertaken, investigators should consider using lower doses of diazoxide (less than 200 mg), which may minimize adverse events and consequent withdrawals, although it may also limit the potential antidepressant effect of this agent. It should be noted that the increased need for novel antidepressants may warrant future studies targeting the EAAT2 promoter as a screening paradigm for identifying novel compounds capable of regulating perturbed glutamate transport at the synapse. 15 AUTHOR DISCLOSURE INFORMATION Funding for this work was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIA-MH002857; NCT02049385), by a NARSAD Independent Investigator Award to Dr Zarate and by a Brain and Behavior Mood Disorders Research Award to Dr Zarate. Dr Zarate is listed as a coinventor on a patent for the use of ketamine and its metabolites in major depression and suicidal ideation. Dr Zarate is listed as a coinventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. Dr Zarate is listed as coinventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders; he has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
